US Edition
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
Summary by Macau Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Kintor [Newsroom]Suzhou, China (ots/PRNewswire) - Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II of the main clinical trial for the KX-826 tincture 1.0% developed by it and potentially first-class ... Continue reading here...Original content of: Kintor, news transmitted by currently
Laotian TimesReposted by 
Macau Business
Macau BusinessPhase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 25, 2025 /PRNewswire/ — The Kintor Pharmaceutical Limited (the “Company“) is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its […]
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
